Conversely, muscle- [14] or adipocyte-specific PPARγ deletion promotes hepatic steatosis [15], which is consistent with the idea that PPARγ activity in adipose, and perhaps muscle, mediates much of Pio's efficacy towards NAFLD [16]. This evidence concerns the gene PPARG and fatty liver disease.